[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337929-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337929-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-mutational-signatures-identification-in-clinical-assays-using-neural-embedding-based-representations","Cancer mutational signatures identiﬁcation in clinical assays using neural embedding-based representations","","Yaacov and colleagues develop MESiCA, a neural embedding-based representation model to predict dominant mutational signatures from targeted gene panel sequencing, the main clinical assay setting. The approach learns mutation-to-signature connections and enables robust signature inference using only a few mutations. Across more than 60,000 tumors, predicted signatures map signature landscapes across cancers and support clinical biomarker uses, including drug response, drug resistance, and prognostication, with a specific link to APOBEC-related EGFR-TKI resistance in NSCLC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-mutational-signatures-identification-in-clinical-assays-using-neural-embedding-based-representations/337929/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-mutational-signatures-identification-in-clinical-assays-using-neural-embedding-based-representations/337929.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does MESiCA address in clinical mutational signature testing?","Question",{"text":63,"@type":64},"Clinical use of mutational signatures is limited because signature detection typically requires broad genomic coverage and enough mutations. MESiCA enables dominant signature prediction using targeted gene panel data with only a few mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does MESiCA perform mutational signature prediction?",{"text":68,"@type":64},"MESiCA is a neural embedding model that learns and embeds specific mutation–signature connections, generating mutational and signature representations used for prediction.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical value do the predicted mutational signatures provide?",{"text":72,"@type":64},"Dominant signature predictions support biomarker applications for drug response, drug resistance, and prognostication, including identification of APOBEC-related EGFR-TKI resistance in NSCLC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337929,1790368819,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Article  \nCancer mutational signatures identiﬁcation in clinical assays using neural embedding-based representations  \nGraphical abstract Authors  \nNeural embeddings model creates mutationaland signature representations  \nMut1  \n(0.71,...,0.82)  \n.  \n.  \n.  \nMut2  \n(0.85,...,0.92)  \n.  \n.  \n.  \nMut3  \n(0.91,...,0.66)  \nSig1  \n(0.75,...,0.99)  \n.  \n.  \n.  \nSig2  \n(0.63,...,0.71)  \n.  \n.  \n.  \nSig3  \n(0.66,...,0.88)  \nWES  \nmutations  \nNeural embedding architecture  \nMESiCA  \nrepresentations  \nTargeted sequencing  \nPrediction of mutational signatures in targeted gene panels  \nLandscape across >60,000 tumors  \nDrug response Drug resistance Prognostication  \nAdar Yaacov, Gil Ben Cohen,  \nJakob Landau, Tom Hope, Itamar Simon, Shai Rosenberg  \nCorrespondence  \nadar.yaacov@mai[l.huji.ac.il](l.huji.ac.il) (A.Y.), [shair@hadassah.org.il](shair@hadassah.org.il) (S.R.)  \nIn brief  \nYaacov et al. develop a neural embedding model for predicting mutational signatures in targeted gene panels, the main sequencing technology used in clinical settings. The model, MESiCA, enables prediction of dominant signatures with only a few mutations. MESiCA demonstrates that mutational signatures are useful biomarkers for drug response, drug resistance, and prognostication.  \nHighlights  \nd AI neural embedding model creates speciﬁc mutational and signature representations  \nd Dominant signature prediction across >60,000 targeted panel tumors  \nd Signatures can be useful biomarkers for drug response, drug resistance, and prognosis  \nd We identify APOBEC-related EGFR-TKI resistance in NSCLC  \nYaacov et al., 2024, Cell Reports Medicine 5, 101608  \nJune 18, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101608](https://doi.org/10.1016/j.xcrm.2024.101608)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nCancer mutational signatures identiﬁcation in clinical assays using neural embedding-based representations  \nAdar Yaacov,1,2,3,5,* Gil Ben Cohen,1,2 Jakob Landau,1,2 Tom Hope,4 Itamar Simon,3 and Shai Rosenberg1,2,6,*  \n1Gafﬁn Center for Neuro-Oncology, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel  \n2The Wohl Institute for Translational Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel  \n3Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel  \n4School of Computer Science and Engineering, Hebrew University of Jerusalem, Jerusalem, Israel  \n5X (formerly Twitter): @AdarYaacov  \n6Lead contact  \n*Correspondence: adar.yaacov@mail.huji.ac.il (A.Y.), [shair@hadassah.org.il](shair@hadassah.org.il) (S.R.) [https://doi.org/10.1016/j.xcrm.2024.101608](https://doi.org/10.1016/j.xcrm.2024.101608)  \nSUMMARY  \nWhile mutational signatures provide a plethora of prognostic and therapeutic insights, their application in clinical-setting, targeted gene panels is extremely limited. We develop a mutational representation model (which learns and embeds speciﬁc mutation signature connections) that enables prediction of dominant signatures with only a few mutations. We predict the dominant signatures across more than 60,000 tumors with gene panels, delineating their landscape across different cancers. Dominant signature predictions in gene panels are of clinical importance. These included UV, tobacco, and apolipoprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) signatures that are associated with better survival, independently from mutational burden. Further analyses reveal gene and mutation associations with signatures, such as SBS5 with TP53 and APOBEC with FGFR3S249C. In a clinical use case, APOBEC signature is a robust and speciﬁc predictor for resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) . Our model provides an easy-to-use way to detect signatures in clinical setting assays with ma","cbCaitMAOulLJaek","https://ap.wps.com/l/cbCaitMAOulLJaek","pdf",8614381,21,"English","# In brief\n# Highlights\n# Summary\n# Introduction\n# Results and clinical applications","[{\"question\":\"What problem does MESiCA address in clinical mutational signature testing?\",\"answer\":\"Clinical use of mutational signatures is limited because signature detection typically requires broad genomic coverage and enough mutations. MESiCA enables dominant signature prediction using targeted gene panel data with only a few mutations.\"},{\"question\":\"How does MESiCA perform mutational signature prediction?\",\"answer\":\"MESiCA is a neural embedding model that learns and embeds specific mutation–signature connections, generating mutational and signature representations used for prediction.\"},{\"question\":\"What clinical value do the predicted mutational signatures provide?\",\"answer\":\"Dominant signature predictions support biomarker applications for drug response, drug resistance, and prognostication, including identification of APOBEC-related EGFR-TKI resistance in NSCLC.\"}]","Cancer mutational signatures identiﬁcation in clinical assays using neural embedding-based representations | PDF",1790021217,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b279218de5cc03e881b02027a66955d.webp",983,1276,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fbe335c3c44228cca013c1df252ddf4.webp",982,1275,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/573796d2a9b4335849ffa322e7316815.webp",981,1273,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/828e3957b9da38f2f5d3c9ee81a5fb64.webp",980,1272]